Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 17/20 | 0.59 |
| ▸ | IGF1R | P08069 | 1/20 | 0.56 |
| ▸ | ATR | Q13535 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL594237 | 0.81 | TNK2 (0.63) | TNK2IGF1R | |
| SCHEMBL593552 | 0.81 | TNK2 (0.59) | TNK2IGF1REGFR | |
| SCHEMBL8240001 | 0.79 | TNK2 (0.83) | TNK2IGF1R | |
| SCHEMBL594616 | 0.78 | TNK2 (0.55) | TNK2IGF1REGFR | |
| SCHEMBL4360049 | 0.74 | TNK2 (1.00) | TNK2IGF1R | |
| SCHEMBL1128692 | 0.73 | TNK2 (1.00) | TNK2IGF1R | |
| SCHEMBL593697 | 0.72 | IGF1R (0.63) | TNK2IGF1REGFR | |
| SCHEMBL595253 | 0.72 | TNK2 (0.60) | TNK2IGF1REGFR | |
| SCHEMBL23803943 | 0.71 | TNK2 (0.70) | TNK2IGF1R | |
| SCHEMBL399400 | 0.71 | IGF1R (1.00) | TNK2IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165651-A1 | FUSED BICYCLIC mTOR INHIBITORS | OSI Pharmaceuticals, LLC | 2013-06-27 | — | — | US | disclosed |
| US-20130165651-A1 | FUSED BICYCLIC mTOR INHIBITORS | OSI Pharmaceuticals, LLC | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165651-A1 | FUSED BICYCLIC mTOR INHIBITORS | MTOR, RICTOR, MAPKAP1 | TNK2 669/4885IGF1R 1033/4885ATR 3253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.